Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
ROMK Inhibitor
VU590 dihydrochloride is a potent inhibitor of the renal outer medullary potassium channel (ROMK, Kir1.1) with an IC50 of 290 nM. It also exhibits inhibitory activity against Kir7.1, with an IC50 of 8 μM. This compound is valuable for research applications investigating potassium channel physiology and associated renal functions, although it may not be ideal for probing ROMK function specifically in kidney tissue. -
K+ Channel Inhibitor
Maurotoxin is a 34-residue peptide that acts as a potent inhibitor of potassium channels, specifically targeting Shaker potassium channels (ShB). With an IC50 value of 2 nM, Maurotoxin effectively attenuates K+ currents, making it a valuable tool for studying ion channel physiology and pharmacology. Its unique structure, characterized by four disulfide bridges, facilitates research into the mechanistic aspects of channel inhibition and potential therapeutic applications in neurobiology. -
Potassium Channel Inhibitor
Kv1.5-IN-1 is a selective inhibitor of the Kv1.5 potassium channel, exhibiting an IC50 value of 0.51 μM in humanKv1.5 channels. The introduction of a methoxy group at the R5 position maintains its inhibitory potency while demonstrating enhanced selectivity—approximately 2,600-fold over compound Ik and 300-fold over compound IId. This high selectivity profile suggests a favorable safety margin, promoting further pharmacodynamic and pharmacokinetic studies. Kv1.5-IN-1 is promising for research into therapies targeting diseases associated with dysfunctional Kv1.5 channel activity. -
Potassium Channel Inhibitor
Pandinotoxin Kα is a potent inhibitor of A-type potassium channels, derived from the venom of the Emperor scorpion (Pandinus imperator). This compound demonstrates significant biological activity by modulating ion channel function, making it a valuable tool for research in neurobiology and cardiovascular studies. Its inhibition of potassium channels has implications for understanding neuronal excitability and therapeutic interventions for channelopathies. -
SK channel/TRPM7 Inhibitor
NS8593 is a selective inhibitor of small conductance Ca2+-activated K+ channels (SK channels), specifically targeting the SK1-3 subtypes. It exhibits a reversible inhibition of SK3-mediated currents with Ca2+-dependent potency (Kd values of 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca2+), while leaving intermediate and large conductance K channels unaffected. Additionally, NS8593 inhibits the TRPM7 channel with an IC50 of 1.6 mM. This compound is valuable for research into central nervous system-related diseases and the physiological roles of SK and TRPM7 channels. -
TREK-1 Inhibitor
TWIK-1/TREK-1-IN-1 is an inhibitor of the TREK-1 potassium channel, a member of the two-pore domain potassium channel family. By targeting both TREK-1 homodimers and TWIK-1/TREK-1 heterodimers, it exhibits IC50 values of 9.36 μM and 14.6 μM, respectively. This compound is significant for research into antidepressant mechanisms, demonstrating potential antidepressant-like effects that warrant further investigation in neuropharmacology. -
Potassium Channel Inhibitor
L-691121 is a potent potassium channel inhibitor that demonstrates antiarrhythmic efficacy by blocking potassium channels, leading to a prolonged cardiac action potential. This compound is orally bioavailable and has been shown to induce embryotoxicity, with fetal mortality noted at a dosage of 0.8 mg/kg/day. Its biological activity makes L-691121 a valuable tool in the study of cardiac function and developmental toxicity. -
Nav1.8 Inhibitor
Nav1.8-IN-7 is a selective inhibitor of the Nav1.8 ion channel, demonstrating over 50% inhibition at a concentration of 100 nM. This compound selectively targets Nav1.8 while exhibiting an IC50 for hERG of 15.6 μM. Nav1.8-IN-7 is particularly relevant for research in pain mechanisms and the development of analgesic therapies. -
Kv1.5 Potassium Channel Inhibitor
DDO-02001 is a moderately potent inhibitor of the Kv1.5 potassium channel, exhibiting an IC50 value of 17.7 μM. This compound is utilized in research focused on understanding anti-arrhythmic mechanisms and the modulation of cardiac excitability. Its selective inhibition of Kv1.5 channels positions DDO-02001 as a valuable tool in the study of cardiac arrhythmias and related therapeutic interventions. -
Potassium Channel Inhibitor
Meglitinide is an ATP-sensitive potassium (KATP) channel inhibitor that selectively targets the SUR1, SUR2A, and SUR2B subunits. It exhibits IC50 values of 0.26 μM, 0.53 μM, and 1.6 μM for these channels, respectively, and demonstrates strong binding affinity with Kd values of 7 μM for SUR1 and SUR2A, and 8 μM for SUR2B. Meglitinide effectively closes KATP channels by binding to a shared site across all SUR subtypes, maintaining its efficacy even with the SUR1 S1237Y mutation. This compound is valuable for research applications centered on type 2 diabetes and the modulation of insulin secretion. -
Peptidyl Inhibitor
Kaliotoxin is a peptidyl inhibitor that targets neuronal BK-Type channels. It specifically inhibits voltage-gated (Kv) channels and calcium-activated potassium channels, making it a valuable tool for studying the regulation of membrane potential and neuronal excitability. This compound is particularly useful in research exploring the mechanisms underlying neuronal signaling and potential therapeutic interventions in neurological disorders. -
ROMK Inhibitor
ROMK-IN-32 is a selective inhibitor of the renal outer medullary potassium channel (ROMK), exhibiting an IC50 value of 35 nM. In addition to its primary activity, ROMK-IN-32 demonstrates inhibition of the hERG channel with an IC50 of 22 μM. This compound is valuable for research applications investigating potassium ion channel regulation, renal physiology, and potential implications in cardiac safety assessments. -
TREK-1 Inhibitor
TWIK-1/TREK-1-IN-3 is a potent inhibitor of the TREK-1 potassium channel, a member of the two-pore domain potassium (K2p) channel family. This compound selectively targets the TREK-1 homodimer and the TWIK-1/TREK-1 heterodimer with IC50 values of 9.74 μM and 16.5 μM, respectively. Its inhibition of TREK-1 is associated with notable antidepressant-like effects, making it a valuable tool for research in depression and related disorders. -
KCa2.1 Inhibitor
B-TPMF is a selective inhibitor of the KCa2.1 channel, demonstrating an IC50 value of 30 nM. This compound engages in a competitive functional interaction with CM-TPMF. B-TPMF is utilized in research applications exploring calcium-activated potassium channels, contributing to the understanding of various physiological processes and potential therapeutic targets. -
Daul TREK-1/TREK-2 Inhibitor
ONO-9517601 is a potent and selective dual inhibitor of TREK-1 and TREK-2 channels, with IC50 values of 0.067 μM and 0.23 μM, respectively. This compound effectively penetrates the central nervous system and demonstrates strong efficacy in the MK-801-induced novel object recognition task in rats. ONO-9517601 is suitable for research on neurological and cognitive disorders, providing insights into the mechanisms of these conditions. -
Daul TREK-1/TREK-2 Inhibitor
ONO-7927846 is a selective dual inhibitor of TREK-1 and TREK-2 channels, exhibiting potent activity with IC50 values of 0.11 μM for TREK-1 and 0.29 μM for TREK-2. This compound demonstrates significant efficacy in preclinical models, particularly in the MK-801-induced novel object recognition paradigm, highlighting its potential in research on neurological and cognitive disorders. ONO-7927846 is suitable for investigating the therapeutic implications of modulating these potassium channels in various CNS-related conditions. -
hERG Inhibitor
hERG-IN-2 is a potent inhibitor of the human Ether-à-go-go-Related Gene (hERG) potassium channel, demonstrating an IC50 of less than 2 μM. This compound is valuable for investigating the role of hERG channel activity in cancer research, making it a useful tool for studying tumor cell proliferation and apoptosis. Researchers can utilize hERG-IN-2 to explore therapeutic strategies targeting hERG-related pathways in oncology. -
Potassium Channel Inhibitor
Noxiustoxin is a potent inhibitor of voltage-dependent potassium channels, specifically Kv1.3, with an IC50 of 360 nM, as well as calcium-activated potassium channels. Derived from the venom of the Mexican scorpion Centruroides noxius, this peptide is significant in the study of neuroinflammatory diseases. Noxiustoxin serves as a valuable tool for researchers investigating ion channel functions and their roles in various physiological and pathological processes. -
Kv4.2 Inhibitor
Heteropodatoxin-2 is a peptide consisting of 30 amino acids that acts as a selective inhibitor of the Kv4.2 potassium channel. This compound effectively blocks Kv4.2 currents expressed in Xenopus laevis oocytes in a voltage-dependent manner, exhibiting reduced inhibition at depolarized potentials. Heteropodatoxin-2 is valuable for studying ion channel physiology and the role of Kv4.2 in cardiac and neuronal signaling pathways. -
HCN2 Inhibitor
HCN2 modulator-5 is a selective inhibitor of the HCN2 ion channel. This compound effectively reduces HCN2 channel activity, making it a valuable tool for investigating mechanisms underlying pain, inflammatory conditions, neuropathic pain, and tinnitus. Additionally, HCN2 modulator-5 can contribute to research focused on central nervous system and psychiatric disorders, including mood disorders. -
Potassium Channel Inhibitor
CK-1649 chloride is a selective potassium channel inhibitor recognized for its class III antiarrhythmic properties. By inhibiting potassium channel activity, this compound plays a crucial role in the modulation of cardiac action potentials and is relevant in researching arrhythmia mechanisms and potential therapeutic interventions in cardiac conditions. Its application in pharmacological studies makes it a valuable tool for investigating ion channel dynamics. -
Potassium Channel Inhibitor
HsTX1 is a potent inhibitor of potassium channels, specifically Kv1.3, with an IC50 of 12 pM. This 34-residue peptide, derived from the scorpion Heterometrus spinnifer, is stabilized by four disulfide bonds. HsTX1 plays a critical role in modulating immune responses by inhibiting TEM cell activation and reducing inflammation in autoimmune conditions, making it a valuable tool for research in these areas. -
Potassium Channel Inhibitor
BDS-I is a potent potassium channel inhibitor specifically targeting the Kv3.4 subtype. This marine-derived toxin, extracted from Anemonia sulcata, effectively inhibits the Aβ1-42-induced enhancement of Kv3.4 activity, caspase-3 activation, and abnormal nuclear morphology in NGF-differentiated PC-12 cells. BDS-I demonstrates protective effects against Aβ peptide-induced cell death, making it a valuable tool for research into neurodegenerative diseases and cellular apoptosis pathways. -
Kv1.3 Inhibitor
UK-78282 hydrochloride is a selective inhibitor of the potassium channel Kv1.3, exhibiting an IC50 of 200 nM. This compound effectively suppresses the activation of human T-lymphocytes in vitro, making it a valuable tool for immunology research. UK-78282 hydrochloride binds to residues on the inner surface of the Kv1.3 channel, overlapping with the binding site of verapamil, thereby enhancing the understanding of ion channel modulation in immune responses. -
hERG Inhibitor
ERG-IN-5 is a potent hERG potassium channel inhibitor, demonstrating an IC50 value of 1.5 μM. This compound exhibits significant cytotoxicity towards MTAPdel HCT116 cells, with a CC50 of 28 nM. ERG-IN-5 is valuable for research applications focused on colon cancer, facilitating the exploration of mechanisms related to potassium channel modulation and cancer cell viability. -
HERG Channel Inhibitor
GPV574 is a potent inhibitor of the HERG potassium channels, with an IC50 value of 5.04 μM. This compound is a derivative of the antiarrhythmic agent propafenone and is employed in research investigating cardiac electrophysiology and drug-induced arrhythmias. Its ability to modulate ion channel activity makes it a valuable tool in the study of heart rhythm disorders. -
Potassium Channel Inhibitor
Stromatoxin 1 is a selective inhibitor of potassium channels, specifically targeting K(V)2.1, K(V)2.2, and K(V)4.2 subunits. This peptide, derived from tarantulas, has been shown to effectively modulate smooth muscle contractions in the urinary bladder by inhibiting the activity of K(V)2.1 and K(V)2.2 channels, while having no effect on K(V)4.2. It serves as a valuable tool for research into bladder physiology and the electrophysiological properties of potassium channels. -
hERG Channel Inhibitor
5-O-Desmethyl donepezil is a metabolite of Donepezil that functions as an inhibitor of the hERG potassium channel with an IC50 of 1.5 μM. This compound is particularly relevant for studies examining cardiac ion channel activity and drug interactions affecting cardiac repolarization. Its potential applications include assessing safety profiles for drug candidates in pharmacological research. -
Kv1.5. Potassium Channel Inhibitor
RH01617 is a selective inhibitor of the Kv1.5 potassium channel, known to modulate cardiac repolarization. This compound exhibits potential for research applications related to atrial fibrillation and other cardiovascular disorders. Additionally, RH01617 also functions as an MMP-13 inhibitor, suggesting a broader scope of biological activity in tissue remodeling processes. -
KV1.3 Channel Inhibitor
ShK toxin is a potent inhibitor of the voltage-dependent potassium channel (Kv1.3), derived from the Caribbean sea anemone Stichodactylus helianthus. This toxin competitively interacts with dendrotoxin I and α-dendrotoxin at synaptosomal membranes, enhancing acetylcholine release. In addition to its neural effects, ShK toxin effectively suppresses K+ currents in cultured rat dorsal root ganglion neurons and demonstrates significant inhibition of T lymphocyte proliferation. It serves as a valuable tool in studies of neurophysiology and immunology. -
Kir2 Inhibitor
ML-133 is a selective inhibitor of the Kir2 family of potassium channels, exhibiting an IC50 of 1.8 μM at pH 7.4 and 290 nM at pH 8.5. This compound serves as a valuable tool for investigating the role of Kir2 channels in various physiological processes and pathophysiological conditions. Its ability to modulate potassium ion flow makes it applicable in studies related to cardiac function, neuronal signaling, and other cellular activities influenced by Kir2 channel activity. -
Kv 1.5 Inhibitor
BMS-394136 is a selective inhibitor of the Kv 1.5 potassium channel, exhibiting an IC50 of 0.05 μM. This compound effectively prolongs the atrial effective refractory period (AERP) and action potential duration (APD) in a dose-dependent manner while leaving the ventricular effective refractory period (VERP) unaffected. BMS-394136 is particularly useful for research focused on acute atrial ischemia and related cardiac electrophysiological studies. -
Ion Channel Inhibitor
Nerispirdine is an ion channel inhibitor that selectively targets voltage-gated potassium channels K(v)1.1 and K(v)1.2, exhibiting IC50 values of 3.6 µM and 3.7 µM, respectively, and also inhibits voltage-dependent sodium channels with an IC50 of 11.9 µM. As a derivative of 4-aminopyridine, Nerispirdine serves as a valuable tool in the investigation of neurological disorders, contributing to research focused on channelopathies and synaptic transmission. Its potential for modulating ion channel activity makes it a significant compound for studying electrophysiological processes. -
Kv1.5 Channel Inhibitor
MSD-D is a potent Kv1.5 channel inhibitor, exhibiting a frequency-dependent mechanism with an IC50 value of 0.5 μM. This compound is promising for research into atrial-selective class III antiarrhythmics, offering potential insights into cardiac arrhythmias and related therapies. -
hERG Inhibitor
6-O-Desmethyl donepezil is a potent hERG channel inhibitor, exhibiting an IC50 value of 1 μM. As a metabolite of Donepezil, it is instrumental in studying cardiac ion channel activity and the potential implications of drug interactions. This compound is valuable for research in cardiotoxicity and pharmacology, particularly in the context of drug development and assessment of cardiac safety profiles. -
bTREK-1 Potassium Channel Inhibitor
6-Bnz-cAMP (N6-Benzoyl-cAMP) is a potent inhibitor of the bTREK-1 potassium channel, functioning through a protein kinase A (PKA) independent mechanism. This compound is instrumental in investigating the roles of signal transduction proteins within the cAMP signaling pathway. Its use can aid in elucidating the physiological and pathophysiological processes mediated by bTREK-1 and cAMP-related signaling cascades. -
Potassium Channel Inhibitor
(BrMT)2 is a non-peptide potassium channel inhibitor that primarily targets Kv1.1 channels. It effectively slows the activation kinetics of these channels, making it a valuable tool for elucidating the physiological roles of potassium channels in various cellular processes. This compound is useful in research applications focusing on neurophysiology, cardiac function, and other studies involving ion channel modulation. -
Potassium Channel Inhibitor
CS476 is a potent inhibitor of potassium channels, exhibiting significant hypoglycemic activity. This compound may facilitate research into the modulation of glucose homeostasis and has potential applications in the study of diabetes-related pathways. Its ability to influence potassium channel activity makes it a valuable tool for investigating various cellular processes linked to metabolic regulation. -
Proton Pump Inhibitor
Zastaprazan citrate is a proton pump inhibitor that functions as a potent potassium-competitive acid blocker. This compound is primarily utilized in research related to gastrointestinal inflammatory disorders and gastric acid-related conditions, including gastroesophageal reflux disease. Its ability to effectively inhibit gastric acid secretion makes it a valuable tool for studying underlying mechanisms of these diseases. -
Proton Pump Inhibitor
Azeloprazole sodium is a potent proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. This compound is primarily used in research related to gastroesophageal reflux disease (GERD), facilitating studies on acid-related gastrointestinal disorders and therapeutic interventions. Its mechanism of action provides valuable insights into the regulation of gastric proton pumps and their role in acid-mediated conditions. -
PM Ca2+-ATPase Inhibitor
Caloxin 2A1 is a selective inhibitor of the plasma membrane Ca2+-ATPase (PMCA), functioning at the extracellular level. This peptide demonstrates a targeted inhibition of PMCA activity without influencing basal Mg2+-ATPase or Na+-K+-ATPase activity. It serves as a valuable tool in studies investigating calcium homeostasis and its implications in cellular signaling and physiology. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan hydrochloride is a potassium-competitive acid inhibitor that selectively targets H+, K+-ATPase, providing a mechanism of action distinct from traditional proton pump inhibitors. By reversibly binding in a potassium-competitive manner, Abeprazan hydrochloride effectively reduces gastric acid secretion without requiring acid activation. This compound is being investigated for its therapeutic potential in treating various acid-related gastrointestinal disorders. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan is a potassium-competitive acid inhibitor primarily targeting the H+, K+-ATPase enzyme. By reversibly binding to this enzyme through potassium-competitive ionic interactions, it effectively reduces gastric acid secretion without the need for acid activation. Abeprazan is being developed as a potential alternative to traditional proton pump inhibitors for the management of acid-related disorders, providing a novel approach to acid control in clinical applications. -
v-ATPase Inhibitor
Verucopeptin is a selective v-ATPase inhibitor that targets the ATP6V1G subunit, effectively reducing v-ATPase activity. This compound has a notable impact on HIF-1 signaling, decreasing the expression of HIF-1α and its target genes. Additionally, Verucopeptin demonstrates antitumor properties against multidrug resistant (MDR) cancers, making it a valuable tool for cancer research. Its specific mechanism and biological activity position it as a significant reagent for studies focused on tumor biology and therapy resistance. -
H+/K+-ATPase Inhibitor
(R)-Tegoprazan is a potent H+/K+-ATPase inhibitor characterized by its benzimidazole structure. It demonstrates an IC50 of 98 nM against canine kidney Na+/K+-ATPase, highlighting its efficacy in modulating ion transport. This compound is prominently applied in research related to gastrointestinal diseases, offering valuable insights into therapeutic interventions. -
Proton Pump Inhibitor
Zastaprazan is a potent proton pump inhibitor that functions as a potassium-competitive acid blocker. It is utilized in research related to gastrointestinal inflammatory diseases and gastric acid-related conditions, including gastroesophageal reflux disease. This compound provides valuable insights into mechanisms of acid secretion and potential therapeutic approaches in the treatment of acid-related disorders. -
Proton-pump Inhibitor
5-Hydroxylansoprazole is a metabolite of Lansoprazole, acting as a proton-pump inhibitor. This compound is instrumental in reducing gastric acid secretion, thereby aiding in the treatment of various peptic disorders. Its primary application in research includes the investigation of acid-related gastrointestinal conditions and the pharmacokinetics of proton-pump inhibitors. -
Proton Pump Inhibitor
Padoprazanum is a proton pump inhibitor that works by irreversibly blocking the H+/K+ ATPase enzyme in the gastric parietal cells. This inhibition effectively reduces gastric acid secretion, making it useful in the treatment of various acid-related gastrointestinal disorders. Key research applications include the investigation of acid secretion mechanisms and the study of therapeutic strategies for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. -
PM H+-ATPase Inhibitor
Protonstatin-1 is a selective inhibitor of the plasma membrane H+-ATPase, exhibiting an IC50 of 3.9 μM. By interacting with the central loop of the enzyme, Protonstatin-1 disrupts the functions of the N- and P-domains, ultimately inhibiting pump activity and auxin transport. This reagent is valuable for research in plant physiology and studies involving cellular ion homeostasis. -
V-ATPase Inhibitor
V-ATPase-IN-1 is a selective inhibitor of Vacuolar-type H+-ATPases (V-ATPase), demonstrating an IC50 value of 194.80 μM and a binding affinity for the V-ATPase subunit A with a Kd of 0.803 μM. This compound exhibits notable insecticidal activity against M. separata, with an LC50 of 2.64 mM. V-ATPase-IN-1 is a valuable tool in research focused on the development of chemical insecticides and understanding the biological role of V-ATPase in various organisms.
